« Zurück
Startseite /
Human PLAU/uPA Protein (active form) (PLA-HM101)

Human PLAU/uPA Protein (active form) (PLA-HM101)

ArtNr	PLA-HM101-100UG
Hersteller	KactusBio
Menge	100 ug
Quantity options	100 ug 500 ug
Kategorie	Oncology Peptides & Proteins Recombinant Proteins By Organ Breast Cancer
Typ	Proteins Recombinant
Format	Lyophilized
Specific against	Human (Homo sapiens)
Host	HEK293
Konjugat/Tag	HIS
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Lyophilized from 0.22μm filtered solution in 25mM HEPES, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
Sequence	Ser21-Leu431
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	PLAU,Urokinase,ATF,UPA,URK,u-PA,BDPLT5,QPD
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	PLAU/uPA
Manufacturer - Conjugate / Tag	C-His
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 17.9 kDa (long chain A), 29.2 kDa (chain B) and 15.3 kDa (N-terminal fragment). The protein migrates to 30-38 kDa and 17 kDa based on Bis-Tris PAGE result.
Description	Recombinant Human PLAU/uPA Protein (active form) is expressed from HEK293 with His tag at the C-Terminus.It contains Ser21-Leu431, which consists of two chains: Long chain A (Ser21-Phe177) and chain B (Ile179-Leu431). The long chain A is further cleaved to yield a short chain A (Lys156-Phe177) and N-Terminus fragment (Ser21-Lys155).
Background	Plasminogen activator, urokinase (uPA) is a secreted serine protease, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. Dysregulation of PLAU is often accompanied by various cancers and PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22 μm filtered solution in 1% HCOOH, 1 mM DTT (pH 3.0). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in 1% HCOOH, 1mM DTT (pH 3.0). It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500ug or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500ug or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

PLA-HM101-100UG-datasheet.pdf

PLA-HM101-100UG-safety-datasheet.pdf